To help you understand what is going on in the drug and pharmaceutical industry and what we expect to happen in the future, our highly experienced Kiplinger Letter team will keep you abreast of the latest developments and forecasts (Get a free issue of The Kiplinger Letter or subscribe). You'll get all the latest news first by subscribing, but we will publish many (but not all) of the forecasts a few days afterward online. Here’s the latest…
At the very least, 2024 will be better than 2023 for the pharma industry. Swiss pharma giant Roche will score the most sales ($55 billion) of any drugmaker next year on the strength of its biologics portfolio, including Ocrevus, a treatment for MS, as well as anti-cancer agent Tecentriq and hemophilia drug Hemlibra.
Johnson & Johnson (JNJ), Merck, AbbVie (ABBV) and Pfizer will exceed $50 billion in sales, too. But Pfizer, the world’s top-selling drugmaker last year, will fall to fifth place due to declining sales for its pandemic-related treatments.
Another notable change: Novo Nordisk will enter the top 10, supplanting GSK (formerly GlaxoSmithKline). Novo Nordisk will boast the two biggest generators of new drug sales, which are both weight loss-related: Wegovy ($4 billion in new sales) and Ozempic ($3 billion).
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Combined, total sales of the drugs, which both employ the same active ingredient, Semaglutide, will rival those of Keytruda, the world’s best-selling pharmaceutical. Keytruda, a cancer immunotherapy drug manufactured and marketed by Merck, will generate over $25 billion this year.
Beyond Keytruda, Wegovy and Ozempic, other top sellers include Sanofi and Regeneron’s Dupixent, which is used to treat allergic diseases like eczema, asthma and nasal polyps, Eliquis, the Pfizer and Bristol Myers Squibb drug used to prevent blood clots, and Gilead’s Biktarvy, a fixed-dose combination medication for the treatment of HIV and AIDS.
This forecast first appeared in The Kiplinger Letter, which has been running since 1923 and is a collection of concise weekly forecasts on business and economic trends, as well as what to expect from Washington, to help you understand what’s coming up to make the most of your investments and your money. Subscribe to The Kiplinger Letter.
Related Content
-
Is the EV Tax Credit Going Away? What You Need to KnowTax Credits There's a lot of chatter about the President-elect's plans to eliminate the electric vehicle tax credit. Here's what's happening.
-
Being Nimble Is Key to This Fidelity Bond Fund's OutperformanceThe Fidelity Total Bond ETF has done well over the long term as managers adjust to changing tides.
-
Kiplinger Outlook: Telecom Companies Brace for Tough TimesThe Letter The telecom industry is entering a new era that threatens profitability. But the coming Trump administration will make it easier for the major players to adjust.
-
Start-ups Trying to (Profitably) Solve the World’s Hardest ProblemsThe Letter More investors are interested in companies working on breakthrough science to tackle huge societal challenges. The field of deep tech has major tailwinds, too.
-
The Big Questions for AR’s FutureThe Letter As Meta shows off a flashy AR prototype, Microsoft quietly stops supporting its own AR headset. The two companies highlight the promise and peril of AR.
-
China's Economy Faces Darkening OutlookThe Letter What the slowdown in China means for U.S. businesses.
-
AI Start-ups Keep Scoring Huge SumsThe Kiplinger Letter Investors continue to make bigger bets on artificial intelligence start-ups, even for small teams with no revenue. Some backers think a startling tech breakthrough is near.
-
Should We Worry About the Slowing U.S. EconomyThe Letter With the labor market cooling off and financial markets turning jittery, just how healthy is the economy right now?
-
New Phones Get All the Hype, but Consumers Still Love Old Models
The Letter Even as flashy artificial intelligence features drive sales of new smartphones, used phones continue to fetch big bucks as demand outstrips supply.
-
Starlink's Internet Beamed From Space Is Taking OffThe Kiplinger Letter Satellite broadband provider Starlink is taking over the space market. Amazon’s mega-constellation will soon join the fray, adding to the unprecedented disruption.
